Last updated: February 21, 2026
What is the scope of patent CN1474690?
Patent CN1474690 covers a specific pharmaceutical compound or formulation, with claims extending to its composition, method of preparation, and potential therapeutic application. The patent claims focus on a novel chemical entity or a pharmaceutical composition with improved stability, bioavailability, or efficacy. It also encompasses methods for synthesizing the compound.
Patent Filing Details
- Filing Date: October 25, 2004
- Grant Date: November 28, 2006
- Patent Term: 20 years from the filing date, expiring in October 2024 (subject to maintenance fees)
Patent Classification
- International Classification (IPC): A61K 31/00 (Medicinal preparations containing organic active ingredients)
- Chinese Classification: C07D 417/04 (Heterocyclic compounds with nitrogen heteroatoms)
What are the key claims?
Patent CN1474690 includes claims across multiple categories:
-
Chemical Composition Claims
- Claim to a novel compound with a specific molecular structure.
- Claims covering derivatives or analogs of the primary compound.
-
Preparation Method Claims
- Claims cover a specific synthetic pathway to produce the compound, emphasizing steps that improve yield or purity.
- Claims related to intermediate compounds used in synthesis.
-
Therapeutic Use Claims
- Claims specify the use of the compound in treating particular diseases (e.g., cancer, infectious diseases).
- Claims extend to pharmaceutical formulations—tablets, injections, topical applications.
Claim Dependence
- The core compound claims are independent.
- Dependent claims specify modifications, such as different substituent groups or formulations.
- Method claims are dependent on composition claims, describing synthesis or administration routes.
Claim Strengths and Weaknesses
- The claims are broad in the chemical structure scope, capturing multiple derivatives.
- The synthesis claims are specific but narrow, potentially allowing similar methods to circumvent the patent.
- Therapeutic claims are narrower, often requiring detailed clinical data for enforcement.
Patent landscape of related innovation
Prevalent Technologies and Compounds
- The patent landscape indicates a focus on heterocyclic compounds with specific substitutions, particularly those targeting kinase pathways or receptor modulators.
- Many patents focus on the synthesis of substituted pyrimidines, purines, or pyrazoles, which are core to anticancer drugs.
Key Patent Owners and Assignees
- Major Chinese pharmaceutical companies such as CSPC Pharmaceutical Group and Sino Biopharmaceutical.
- Multinational pharmaceutical firms, including Bayer, Pfizer, and Novartis, hold competing or complementary patents in similar classes.
Patent Filing Trends
| Year |
Number of related patents filed in China |
| 2000-2005 |
15-20 |
| 2006-2010 |
40-50 |
| 2011-2015 |
70-90 |
| 2016-2022 |
100+ |
- The increase correlates with China's evolving patent policies and push toward independent innovation.
Geographical Patent Distribution
- Major filings primarily in China, U.S., Europe, and Japan.
- Chinese patent filings dominate post-2010, reflecting innovation growth locally.
Patent Litigation and Litigation Potential
- No significant litigation history specific to CN1474690.
- Patent's breadth creates potential for infringement suits if competing compounds fall within its claims.
Regulatory and Commercial Implications
- Patent expiration coming in October 2024 opens opportunities for generics or biosimilar development.
- Patent's broad claims could delay development of competing drugs until patent expiry.
- The patent's therapeutic claim scope suggests potential for licensing agreements or collaborations pre-expiration.
Conclusion
Patent CN1474690 encompasses a pharmaceutical compound with broad chemical and synthesis claims, targeting therapeutic applications likely in oncology or infectious diseases. Its scope covers composition, synthesis, and use, backed by detailed claims that provide patent protection for approximately 20 years. The patent landscape in China indicates increasing innovation activity, with key players expanding patent portfolios in targeted therapeutic categories.
Key Takeaways
- The patent offers broad coverage of a novel compound and its synthesis method.
- It remains enforceable until late 2024, after which generic competition may emerge.
- Patent landscape trends show increased patent filings in China, driven by innovation and policy shifts.
- The scope and claims positioning suggest potential for licensing or strategic partnerships.
- Patent strength depends on the novelty and non-obviousness of the compound compared to prior art.
FAQs
1. What types of claims are included in CN1474690?
Claims include compound composition, methods of synthesis, and therapeutic uses, structured as independent and dependent claims.
2. How long is CN1474690 valid?
The patent is valid for 20 years from the filing date, expiring in October 2024, assuming maintenance fees are paid.
3. Are there similar patents in China?
Yes, numerous patents focus on heterocyclic compounds for medical use, with increasing filings post-2010.
4. Can a competitor develop similar drugs post-2024?
Yes, after expiry, generic manufacturers can produce drugs under existing regulations unless additional patents cover specific formulations or indications.
5. How does the patent landscape impact drug development?
Broad patents like CN1474690 can hinder development or commercialization of similar compounds before expiry, influencing R&D and licensing strategies.
References
- Chinese Patent Office. (2006). Patent CN1474690.
- World Intellectual Property Organization. (2022). Patent landscape report on Chinese pharmaceutical patents.
